

The 9th Santorini Conference

SYSTEMS MEDICINE AND PERSONALISED HEALTH & THERAPY
« The Odyssey from Hope to Practice »

30 September - 3 October 2018

Nomikos Conference Center, Thira-Santorini / Greece



PRELIMINARY SCIENTIFIC PROGRAM (2 October, 2017)
(TBC: To Be Confirmed)

Sunday 30, September

04:00 pm – 06:00 pm – *REGISTRATION*

06:00 pm – 06:15 pm - *WELCOME - Sofia Siest, Nancy, France*

06:15 pm – 07:15 pm - **KEYNOTE LECTURE**

The journey to personalised medicine – landmarks and challenges
Eric Boerwinkle, Houston, USA

WELCOME RECEPTION

Monday 1st, October – 09:00 am to 02:00 pm

09:00 am – 11:00 am - **SESSION I**

'-OMICS' BIOMARKERS COMMONALITY IN CARDIO-METABOLIC DISEASES AND CANCER – CAN SEQUENCING OFFER A DIAGNOSIS?

Chairs: Panagiotis Deloukas, London, United Kingdom /

- Metabolomics applied to novel cardiometabolic disease mechanisms and therapeutic targets
Christopher B. Newgard, Houston, USA
- The 100,000 Genomes Project- transforming genomics in healthcare
Mark Caulfield, London, UK
- The International Cancer Genome project
(TBA)
- Personalised biomarkers in cancer
Eleftherios Diamandis, Toronto, Canada

11:00 -12:00 – **Coffee Break**

11:00 pm – 12:00 pm – **COMMITTEE POSTERS VISIT**

12:00 am – 02:00 pm – **SESSION II**

UNMET CLINICAL NEEDS IN THE PREVENTION AND TREATMENT OF CARDIO-METABOLIC DISEASES AND CANCER – COMORBIDITIES

Chairs: Athanase Benetos, Nancy, France /

- Epigenetics of Cardiovascular Diseases and co-morbidities
Manuel Rosa Garrido, Los Angeles, USA
- Telomere length and the Cancer/Atherosclerosis trade off
Abraham Aviv, New Jersey, USA
- Predicting the risk of Cardiovascular co-morbidities in adult cancer survivors
Winson Y. Cheung, Vancouver, Canada (TBC)
- Heart failure, aging and co-morbidities: New therapeutic approaches
Athanase Benetos, Nancy, France

02:00 pm – 05:00 pm – **FREE TIME**

03:00 pm – 05:00 pm – **CLOSED MEETING – MAST4HEALTH**

04:00 pm – 05:00 pm – **COMMITTEE POSTERS VISIT**

Monday 1 October – 05:00 pm to 08:00 pm

05:00 pm – 07:00 pm – **SESSION III**

PIPELINE CHALLENGES IN PRECISION MEDICINE – FROM PATIENT SAMPLING TO A CLINICAL REPORT

Chairs: George Dagher, Paris, France /

- From Patient sampling to clinical report – The Austrian experience
Markus Paulmichl, Salzburg, Austria
- Standardized improved pre-analytical workflows: the bridge to good quality samples for reliable analytical test results
Uwe Oelmueller, Hilden, Germany
- Using tissue samples for quantitative protein and phosphoprotein analysis – critical considerations
Karl Friedrich Becker, Munich, Germany
- Challenges in using liquid biopsies for precision medicine
Maria G. Daidone, Milan, Italy

07:00 pm – 08:00 pm – **SESSION IV**

PGX – THE REGULATORY AND INDUSTRIAL PERSPECTIVE

Chairs: Markus Paulmichl, Salzburg, Austria / Lynn Webster, Salt Lake City, United States

- EMA Good Pharmacogenomic Practice (GPP) group EMA: Pharmacogenomics Working Party: Relevant new Guidelines
Markus Paulmichl, Salzburg, Austria
- I-PWG: Industry – Pharmacogenomics Working group: Upcoming Challenges in PGx for the Industry – Speaker: *(to be named by I-PWG) (TBC)*

9:00 pm – GALA DINNER

Tuesday 2 October – 09:00 am to 02:00 pm

09:30 am – 11:30 am – SESSION V

GENE-ENVIRONMENT INTERACTIONS IN CARDIO-METABOLIC DISEASES AND CANCER

Chairs: Robert Barouki, Paris, France /

- Gene-environment interactions in cardio-vascular diseases: ‘-omics’ and systems biology
Myriam Fornage, *Houston, US*
- A perspective on interaction effects in genetic association studies - Variation in Predictive Ability of Common Genetic Variants by Established Strata: The Example of Breast Cancer and Age
Hugues Aschard, *Paris, France*
- Nutrigenetics in Non-Alcoholic Fatty Liver Disease
Georges Dedoussis, *Athens, Greece*
- Exposome/epigenomics and clinical application
Robert Barouki, *Paris, France*

11:30 am - 12:00 am – Coffee Break

12:00 am – 02:00 pm - SESSION VI

WHAT CAN WE LEARN FROM ELECTRONIC HEALTH RECORDS?

Chairs: Panagiotis Deloukas, London, United Kingdom /

- Using Big Data to interpret genomes to accelerate drug discovery
Rong Chen, *Mount Sinai, US*
- Linking HER to genetic data
Harry Hemingway *London, UK*
- Primary health data in a cohort of over 20,000 people in East London
Richard Trembath, *London, UK*
- Linking genetic data to risk of recurrent cardiovascular events through hospital records
Panagiotis Deloukas, *London, UK*

02:00 pm – 04:00 pm – FREE TIME

04:00 pm – 05:00 pm –

Tuesday 2 October - 05:00 pm to 07:00 pm

05:00 pm – 07:00 pm - SESSION VII

PAIN MANAGEMENT - A 'JOURNEY' FROM 'CLINICAL TRIAL' VIA 'POST-MARKETING PHARMACOVIGILANCE / RISK MANAGEMENT' TO 'SUCCESS STORY'

Chairs: Michael Marschler, Mannheim, Germany / Lynn Webster, Salt Lake City, USA

- The journey starts with “Genetic biomarkers as common denominators for specific pain disorders”
Lynn Webster, *Salt Lake City, USA*
- 1st stop over: “Opioid pharmacogenomics”
Laure Elens, *Brussels, Belgium*
- 2nd stop over: “Pharmacogenomics in Post-Marketing Pharmacovigilance”
Marta Armogida, *Mannheim, Germany*
- End of the journey: “The adoption of Pharmacogenomics leading to patient benefit”
Andrew Purchase, *Swansea, UK*

07:00 pm – 08:00 pm - YOUNG INVESTIGATORS LECTURES

- 6 x 10 min oral presentations

Wednesday 3 October - 09:00 am to 02:00 pm

09:00 am – 11:00 am - SESSION VIII

PHARMACOGENOMICS: CHALLENGES OF CLINICAL TRANSLATION

Chairs: Urs Meyer, Basel, Switzerland / Charity Nofziger, Salzburg, Austria

- Safety of drug treatment in oncology: A genomic perspective
Federico Innocenti, *Chapel Hill, USA*
- Technical Challenges in CYP2D6 analysis
Charity Nofziger, *Salzburg, Austria*
- Pharmacogenomics – A paradigm for digital medicine
Urs A. Meyer, *Basel, Switzerland*
- Taking biomarkers from discovery to implementation in clinical practice
Munir Pirmohamed, *Liverpool, UK*

11:00 am - 11:30 am – Coffee Break

11:30 am – 01:30 pm - SESSION IX

LATEST INSIGHTS IN STROKE: CLINICAL TRIALS AND APPLICABILITY OF ‘-OMICS’ DATA IN PATIENT’S STRATIFICATION

Chairs: John Lamont, Belfast, United Kingdom /

- Genetics of cerebrovascular disease
Stéphanie Debette, *Bordeaux, France*
- ‘-Omics’ determinants of subclinical stroke events
Sudha Seshadri, *Boston, US*
- Stroke and pharmacogenomic’s
Guillaume Pare, *Hamilton, Ontario, Canada*
- Protein Biomarkers and diagnosis of ischemic stroke
Konstantinos Makris, *Athens, Greece*

01:30 pm – 02:00 pm

CONCLUSIONS & PERSPECTIVES REMARKS

by **Sofia Siest**, *Nancy, France* and **Urs Meyer**, *Basel, Switzerland*

